Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease

Model scores of the 29,894 trials active now.

Model score 29% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (446 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2011-02-28. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: to determinescancardiacmriventricular
  Phrases that lowered it: evaluatetumorsadvancedrangepharmacokinetic
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports with a death: 29.4% (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Responsible party: not given (raises risk) · Design
• Design: single group (raises risk) · Design
• Sponsor's past trials: 1 (raises risk) · Sponsor's track record
• Disease area, neurology: Yes (raises risk) · Disease area
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: 98.4% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Maximum age: 90 (lowers risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Number of arms: not given (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Blinding: none (raises risk) · Design
• Disease area, dermatology: No (lowers risk) · Disease area
• Keywords listed: 3 (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome NCT00673816 · started 2008 · scored riskier than 65% of active trials terminated
• Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies NCT01243359 · started 2010 · scored riskier than 26% of active trials completed
• Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma NCT00843037 · started 2009 · scored riskier than 99% of active trials completed
• Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment. NCT03066427 · started 2017 · scored riskier than 80% of active trials completed
• Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors. NCT02058901 · started 2013 · scored riskier than 54% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.